Since the group of Aussies have taken over management of Radient Pharmaceuticals, they have looted the company of any remaining assets and transferred them to cstamdl.com, their personal company based in Hong Kong. The cstamdl site claims all previous clinical trial data as their own, they claim to have a manufacturing facility in the USA named AMDL and show pictures of the facility. They even transferred the trademarks owned by Radient to AMDL diagnostics so Radient is left with nothing but debt and disgruntled former shareholders.
Below are the photos of the building the Aussies claim as their own USA facility. View through the front window. View of the entrance where the new sign replaced Radient Pharmaceuticals.
View of the rear door where the sheriff's notice of seizure was removed. View of the reserved parking spot. View through the locked front door of the reception desk. The stock no longer trades.
No company is merging with Radient. Any posts to that effect are just not true. William Gartner has denied any connection with Radient or Provistadx. There is no merger with Radient. http://images.investorshub.advfn.com/images/uploads/2015/3/19/namwhgcdx.jpg Provistadx has repeatedly denied any connection with Radient Pharmaceuticals. Dear Mr. Gartner,
I am intrigued by your recent press release about offering a new Lung Cancer Test.
How do you get your financing? Is there an opportunity for a private investor like me to invest, and if so, how would I accomplish that?
In researching GCDx, I am finding several rumors on the internet (particularly on InvestorsHub.com) that your company is merging with, or taking over, Radient Pharmaceuticals and/or Provista Diagnostics. Is there any truth to that rumor? What is your current business relationship with Radient Pharmaceuticals and Provista Diagnostics? Do you own RXPC stock?
I am concerned that Radient might be carrying a lot of debt -- if you are involved with taking over or merging with Radient, what kind of debt responsibilities are you incurring, and if I invest in your company, how would I know that my money is not going towards paying off Radient's debt?
Finally -- do you have any patents or patent applications for The Lung Cancer Test for Early Detection?
Thank you for your time,
AND HERE IS HIS REPLY:
Before I answer all of your questions, I need to know more about you, especially whether or not you are a qualified investor under Rule 144. I will say this to clear up that very old rumor. We have no connection whatsoever with Radient Pharmaceutical in any way – company-wise or personally.
Do you represent a firm or is this personal? We must be very careful to comply with all of the regulations.
President and CEO
Global Cancer Diagnostics Inc.
2343 W. University Dr.
Tempe, Arizona 85281 USA
602-300-4901 Cell DR70 is used to test for fibrin degradation products. Some posters are not telling the truth when they claim DR70 is used to break down other proteins. That is just a total lie. DR70 is not in any way used by Provistadx. Both Provistadx and William Gartner of GCDX have denied any connection with Radient.
Both issued patents for DR70 has expired and a patent application has received a final rejection. The patent agent has resigned and the patent office has no current address for Radient. Unless the patent office receives a response within 6 months of the rejection, the application will be declared abandoned.
Currently no company using the DR70 fibrin test is required to pay royalties to Radient. Radient has no source of revenue.
A seizure of assets notice is on the door of the former offices of Radient Pharmaceuticals.
Radient did not pay the annual fee to continue product registration with the FDA.
All patents for Onko Sure have now expired and the only patent application remaining has received a final rejection. The patent agent has resigned and there is no longer any current contact address for Radient Pharmaceuticals.
Telephone has been disconnected.
Radient-pharma.com website has been removed from service.
A website in Australia, Radient-diagnostics.com is pending under construction since May 6, 2014.
With penalties and interest, Radient owes the 2011 lenders in excess of $25 million.
Charts: None. The stock no longer trades.
No company is merging with Radient. Any posts to that effect are just not true.